Men with non-metastatic castration resistant prostate cancer have a significant overall survival (OS) benefit with enzalutamide in addition to their conventional androgen deprivation therapy, a study shows. The final OS data of the phase III PROSPER trial presented at the ASCO20 Virtual Scientific Program showed a 27% lower risk of death for patients treated with ...
One year OS benefit with enzalutamide in castration resistant prostate cancer: PROSPER
By Sunalie Silva
17 Jun 2020